Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930 –940]

It has come to our attention that there was a mistake in Fig.  6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure below. We apologize for any inconvenience caused.

Source: Journal of Hepatology - January 29, 2021 Category: Gastroenterology Authors: Taesik Gwag, Zhaojie Meng, Yipeng Sui, Robert N. Helsley, Se-Hyung Park, Shuxia Wang, Richard N. Greenberg, Changcheng Zhou Tags: Erratum Source Type: research